Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17666816 | 0.72 | CETP (0.30) | CETP | |
| SCHEMBL1148821 | 0.69 | CETP (0.33) | CETP | |
| SCHEMBL11996458 | 0.67 | — | — | |
| SCHEMBL22593959 | 0.65 | ALDH1A1 (0.30) | — | |
| SCHEMBL23504288 | 0.65 | — | — | |
| SCHEMBL2067084 | 0.65 | CETP (0.30) | CETP | |
| SCHEMBL2066011 | 0.65 | CETP (0.30) | CETP | |
| SCHEMBL21598031 | 0.65 | — | — | |
| SCHEMBL23504353 | 0.65 | — | — | |
| SCHEMBL17656349 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4626899-A1 | DIRECT SYNTHESIS OF ORGANOTIN ALKOXIDES | Inpria Corporation (US) | 2025-10-08 | — | — | EP | disclosed |
| US-20240199658-A1 | DIRECT SYNTHESIS OF ORGANOTIN ALKOXIDES | INPRIA CORPORATION | 2024-06-20 | — | — | US | disclosed |
| WO-2024118918-A1 | DIRECT SYNTHESIS OF ORGANOTIN ALKOXIDES | INPRIA CORPORATION (US) | 2024-06-06 | — | — | WO | disclosed |
| WO-2017100537-A1 | BETA-LACTAMASE INHIBITORS | VenatoRx Pharmaceuticals, Inc. (US) | 2017-06-15 | — | — | WO | disclosed |
| EP-2274295-B1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-08-05 | — | — | EP | disclosed |
| US-8889714-B2 | 3,4-substituted piperidine derivatives as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-18 | — | — | US | disclosed |
| CN-102015682-B | 3, 4-substituted piperidine derivatives as renin inhibitors | MERCK FROSST CANADA LTD | 2014-07-16 | — | — | CN | disclosed |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK CANADA INC. (CA) | 2011-06-23 | — | — | US | disclosed |
| EP-2300453-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-03-30 | — | — | EP | disclosed |
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2011-03-03 | — | — | US | disclosed |
| EP-2274295-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Merck Frosst Canada Ltd. (CA) | 2011-01-19 | — | — | EP | disclosed |
| EP-2204365-A1 | ALKYLSULFONE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2010-07-07 | — | — | EP | disclosed |
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2010-07-01 | — | — | US | disclosed |
| WO-2009140769-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-26 | — | — | WO | disclosed |
| WO-2009135299-A1 | 3, 4 - SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | MERCK FROSST CANADA LTD. (CA) | 2009-11-12 | — | — | WO | disclosed |
| US-5117055-A | Method for direct conversion of fluorocarbonyl group into halogenides | AGENCY OF INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 1992-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053940-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, ACE2 | CETP 2525/4885 |
| US-20240199658-A1 | DIRECT SYNTHESIS OF ORGANOTIN ALKOXIDES | RTN4, RTN3, PNN | CETP 4673/4885 |
| US-20100168136-A1 | ALKYLSULFONE DERIVATIVES | BACE1, APP, AMY1A | CETP 798/4885 |
| US-20110152316-A1 | 3,4-SUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | REN, ACE, AGTR1 | CETP 3032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.